Key facts
- Condition: obstructive sleep apnea — repeated upper-airway collapse during sleep, graded by the apnea-hypopnea index (AHI).
- Leading modifiable risk factor: excess body weight; abdominal and neck fat narrow and destabilise the airway.
- Key trial: SURMOUNT-OSA — two phase-3 trials of once-weekly tirzepatide vs placebo over 52 weeks (469 participants total).
- Populations: adults with moderate-to-severe OSA and obesity, either not using or using positive airway pressure (PAP) therapy.
- Headline result: AHI fell by about 25 events/hour (not on PAP) and 29 events/hour (on PAP) with tirzepatide, versus roughly 5 on placebo.
- Regulatory outcome: FDA approval of tirzepatide (Zepbound) for moderate-to-severe OSA in adults with obesity — the first drug approved for the condition.
- Registration: NCT05412004 — ClinicalTrials.gov.
- Publication: New England Journal of Medicine, 2024 — PMID 38912654.
What is obstructive sleep apnea?
Obstructive sleep apnea (OSA) is a sleep-related breathing disorder in which the muscles and soft tissue of the upper airway relax and collapse during sleep, repeatedly blocking airflow. Each blockage produces either an apnea — a full pause in breathing — or a hypopnea, a shallow, restricted breath. The brain briefly rouses to reopen the airway, and the cycle repeats, often hundreds of times a night without the sleeper being aware of it.
The severity of OSA is graded by the apnea-hypopnea index (AHI): the average number of apneas plus hypopneas per hour of sleep. Roughly speaking, 5–15 events per hour is mild, 15–30 is moderate, and more than 30 is severe. Because the disorder fragments sleep and repeatedly drops blood-oxygen levels, it is linked to daytime sleepiness, high blood pressure and broader cardiometabolic strain. Continuous positive airway pressure (CPAP) and other positive-airway-pressure devices have long been the mainstay treatment, splinting the airway open with a stream of pressurised air.
How obesity drives sleep apnea
Obesity is one of the strongest and most consistently identified modifiable risk factors for obstructive sleep apnea, and the mechanical link is fairly direct. Fat deposited around the neck and within the tongue and soft palate physically narrows the upper airway, leaving less room for air to pass and a greater tendency for the walls to touch and collapse when muscle tone falls during sleep.
The effect is not only local. Abdominal fat reduces lung volume, and lower lung volume in turn removes some of the downward "tethering" that normally keeps the upper airway stiff and open. Excess weight can also alter the drive and reflexes that stabilise breathing overnight. Put together, these changes mean that as body weight rises, both the frequency and the severity of airway collapse tend to rise with it — which is precisely why weight change has long been understood as a lever on OSA severity, and why a drug that produces large, sustained weight loss was a plausible candidate to test. Our overview of obesity as a treatment target covers that broader picture.
The SURMOUNT-OSA trial
SURMOUNT-OSA was designed to answer a specific question: if excess weight drives obstructive sleep apnea, does a drug that drives large weight loss meaningfully reduce the apnea-hypopnea index? It tested tirzepatide — a once-weekly dual GIP and GLP-1 receptor agonist — against placebo in adults with moderate-to-severe OSA and obesity. The trial was sponsored by Eli Lilly and published in the New England Journal of Medicine in 2024 (PMID 38912654).
It was built as a master protocol with two randomized, double-blind, placebo-controlled arms run over 52 weeks: one in participants who were not using positive airway pressure (PAP) therapy, and one in participants who were using PAP and planned to continue. Splitting the study this way tested tirzepatide both as a stand-alone approach and as an add-on to existing device therapy. Participants assigned to the drug received the maximum tolerated dose of once-weekly tirzepatide (reported in the trial as 10 mg or 15 mg); describing that regimen is reporting what the trial administered, not a dosing instruction. The registration record is NCT05412004. Our dedicated SURMOUNT-OSA summary goes deeper on the design and endpoints.
What the trial found
The primary endpoint was the change in AHI from baseline to week 52. In the participants not using PAP therapy, tirzepatide reduced the apnea-hypopnea index by about 25 events per hour, compared with roughly 5 events per hour on placebo. In the participants using PAP, the reduction with tirzepatide was even larger — about 29 events per hour, versus roughly 5 on placebo.
| Change in AHI at week 52 (events per hour) | Tirzepatide | Placebo |
|---|---|---|
| Trial 1 — participants not using PAP therapy | ≈ −25 | ≈ −5 |
| Trial 2 — participants using PAP therapy | ≈ −29 | ≈ −5 |
Those are large shifts on a scale where the difference between "severe" and "mild" is often a matter of a few dozen events per hour. Alongside the AHI reduction, tirzepatide produced substantial weight loss and improved several secondary sleep-apnea measures. A meaningfully larger share of participants on tirzepatide reached the kind of low-AHI, low-symptom state that clinicians care about than did those on placebo. Reported side effects were consistent with the known profile of the drug class — gastrointestinal effects such as nausea and diarrhea were the most common — which we cover in the tirzepatide research summary and the broader peptides-for-weight-loss evidence map.
The approved OSA indication
SURMOUNT-OSA did something no obesity drug had done before: it moved sleep apnea from a condition managed almost entirely with devices, dental appliances and surgery to one with an approved medication. On the strength of the results, the U.S. Food and Drug Administration approved tirzepatide — marketed for weight management as Zepbound — for moderate-to-severe obstructive sleep apnea in adults with obesity, to be used together with a reduced-calorie diet and increased physical activity.
That approval matters for two reasons. First, it is the first time a drug has been cleared specifically for OSA, giving clinicians a pharmacological option to consider for patients whose sleep apnea is tied to obesity. Second, it reinforces a theme running through the newer incretin-based drugs: a medicine developed around metabolism and weight keeps demonstrating benefit in the downstream conditions that obesity drives — here, a sleep-and-breathing disorder rather than a purely metabolic one. It does not mean the drug is right for everyone with OSA, and it does not retire positive airway pressure as a treatment.
Limitations and what it does not prove
The SURMOUNT-OSA finding is important, but it has boundaries worth keeping in view:
- It studied a specific population. Everyone enrolled had moderate-to-severe OSA and obesity. The result speaks most directly to people like those enrolled — not to sleep apnea driven by anatomy unrelated to weight, or to people without obesity.
- It reports an outcome, not a mechanism. Participants lost significant weight, which is a plausible driver of the lower AHI, but the trial was not designed to prove how much of the benefit came from weight loss versus other effects of the drug.
- It does not make the drug a device replacement. SURMOUNT-OSA showed benefit in people both on and off PAP therapy; it did not establish that a medication should replace CPAP for any given person. That remains a clinical decision.
- It is a comparison against placebo. The trial shows tirzepatide beat placebo on AHI; it does not rank it against other weight-loss drugs, surgery or devices for this outcome, and it measured effects over 52 weeks rather than many years.
None of this diminishes the milestone. It simply keeps it the right size: strong evidence in a defined, high-risk group, and a genuine first for the field. For more on how these agents work and where the evidence is strongest, see our explainer on peptides for weight loss or browse all research articles.
Frequently asked questions
How does obesity cause obstructive sleep apnea?
Excess body weight contributes to obstructive sleep apnea in several ways at once. Fat deposited around the neck and tongue narrows the upper airway, abdominal fat reduces lung volume and the tethering that normally keeps the airway stiff, and both make the airway more likely to collapse during sleep. That is why obesity is one of the strongest modifiable risk factors for the condition, and why weight change is a recognised lever on its severity.
What is the apnea-hypopnea index?
The apnea-hypopnea index, or AHI, counts the average number of apneas (breathing pauses) and hypopneas (shallow breaths) per hour of sleep. It is the standard measure of obstructive sleep apnea severity: roughly 5 to 15 events per hour is mild, 15 to 30 is moderate, and more than 30 is severe. SURMOUNT-OSA used change in AHI as its primary endpoint.
What did the SURMOUNT-OSA trial show?
SURMOUNT-OSA tested once-weekly tirzepatide against placebo in adults with moderate-to-severe obstructive sleep apnea and obesity, across two 52-week trials, one in people not using PAP therapy and one in people using it. Tirzepatide reduced the apnea-hypopnea index by roughly 25 to 29 events per hour, compared with about 5 on placebo, alongside substantial weight loss. It was the first drug shown to meaningfully lower AHI in this population.
Is tirzepatide approved for obstructive sleep apnea?
Yes. On the strength of the SURMOUNT-OSA results, the U.S. Food and Drug Administration approved tirzepatide (marketed as Zepbound) for moderate-to-severe obstructive sleep apnea in adults with obesity, used alongside a reduced-calorie diet and increased physical activity. It was the first medication approved specifically for obstructive sleep apnea rather than as a device or surgery.
Does a weight-loss drug replace a CPAP machine?
Not necessarily. SURMOUNT-OSA enrolled people both on and off positive airway pressure (PAP) therapy and showed benefit in both groups, but it did not establish that a drug should replace PAP for any individual. Continuous positive airway pressure remains a mainstay treatment. Whether to add, change or continue any therapy is a clinical decision made with a sleep specialist, not something to infer from a trial.
Was the sleep apnea benefit just from weight loss?
Participants lost a substantial amount of weight, and reduced weight is a plausible driver of a lower apnea-hypopnea index. But the trial reported a clinical outcome, not a mechanism, so it cannot prove exactly how much of the AHI reduction came from weight loss versus other effects. The result is best read as the observed outcome of the whole intervention in a population defined by obesity and sleep apnea.
Sources
This summary traces to the peer-reviewed publication and trial registration:
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA) — New England Journal of Medicine, 2024; PubMed 38912654.
- SURMOUNT-OSA (tirzepatide in obstructive sleep apnea and obesity) — ClinicalTrials.gov NCT05412004.
- Condition reference record: obstructive sleep apnea.